RVTY
What one share of Revvity holds
Laboratory Analytical Instruments
We are a leading provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
Revvity’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-07-05; the balance sheet is as of 2026-07-05.
| Sales | $25.77 |
|---|---|
| Profit | $2.10 |
| Capex (buildings and equipment) | $0.62 |
| Free cash flow | $4.94 |
| Dividends | $0.28 |
| Cash and investments | $9.17 |
| Debt | $28.88 |
| Book value | $64.78 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $19.18 | $2.12 | $0.29 | $2.89 | $0.28 | $19.65 |
| 2017 | $20.36 | $2.64 | $0.35 | $2.25 | $0.28 | $22.68 |
| 2018 | $24.91 | $2.13 | $0.84 | $1.95 | $0.28 | $23.42 |
| 2019 | $25.86 | $2.04 | $0.68 | $2.58 | $0.28 | $25.32 |
| 2020 | $33.75 | $6.49 | $0.57 | $7.39 | $0.28 | $33.33 |
| 2021 | $32.81 | $8.08 | $0.74 | $11.35 | — | $56.57 |
| 2022 | $26.20 | $4.50 | $0.68 | $4.70 | $0.28 | $58.46 |
| 2023 | $22.04 | $5.55 | $0.65 | $0.08 | $0.28 | $63.79 |
| 2024 | $22.43 | $2.20 | $0.71 | $4.41 | $0.28 | $63.55 |
| 2025 | $24.50 | $2.07 | $0.63 | $4.37 | $0.28 | $64.57 |